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Abstract
Introduction: Acute liver failure is associated with a high mortality rate. Induction of plasma
hypertonicity with mannitol or hypertonic saline remains the cornerstone in the management of
resultant cerebral edema. Signiﬁcant disadvantages of this approach include poor or unpredictable
control of serum sodium concentration and volume expansion, among others.
Methods: We used high sodium continuous veno-venous hemodialysis with regional citrate anticoagulation and online dialysate generation to accurately control the serum sodium in eleven patients
with acute liver failure, renal failure, and cerebral edema. We used a Fresenius 2008 K/K2 machine
in hemodialysis mode to deliver a blood ﬂow of 60 ml/minute and dialysate ﬂow of 400 ml/minute.
Our previously published protocol results in complete removal of infused citrate by the dialyzer. Online clearance calculations were used to model the time required to reach the target serum sodium.
Findings: All patients achieved serum sodium within 2 mEq/L of target without ﬂuctuations or
rebound. Nine patients survived without requiring liver transplantation and two died despite reaching the prescribed serum sodium target. We did not encounter any citrate toxicity.
Discussion: We describe a novel approach for delivering continuous osmotherapy to patients
with acute liver failure, renal failure, and cerebral edema. In comparison to standard therapy, the
described modality enables precise titration of serum sodium without undesirable ﬂuctuations in
extracellular ﬂuid volume. A particular advantage is zero delivery of citrate to this vulnerable group
of patients with acute liver failure.
Key words: Acute liver failure, cerebral edema, continuous veno-venous hemodialysis, regional
citrate anticoagulation, online dialysate generation
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INTRODUCTION
Acute liver failure (ALF) affects approximately 2000 persons annually in the United States1 and is caused by acetaminophen toxicity in about half of the cases.2 Acute
kidney injury (AKI) develops in 75% of cases caused by
C 2017 International Society for Hemodialysis
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Table 1 Patients’ demographics and clinical settings
Case no.
1
2
3
4
5
6
7
8
9
10
11

Age, gender

Etiology of ALF

SOFA score

MELD score

Baseline renal
function

Vaso-pressors

MV

ICP monitor

43, F
50, F
24, F
40, F
34, F
42, F
25, M
19, F
36, F
54, F
44, F

Septic shock
Budd-Chiari
APAP
APAP
APAP
APAP
APAP
APAP
APAP
APAP
Unknown

17
10
14
16
16
14
14
11
14
13
9

39
45
23
35
33
42
45
51
36
37
29

Normal
Normal
Unknown
Normal
Normal
Normal
Unknown
Unknown
Normal
Normal
Normal

Yes
No
Yes
Yes
Yes
Yes
Yes
No
Yes
Yes
Yes

No
No
No
Yes
Yes
No
No
No
Yes
Yes
Yes

No
No
No
Yes
Yes
No
No
No
Yes
Yes
Yes

Patients 2 and 5 did not survive.
ALF 5 acute liver failure; APAP 5 N-acetyl-para-aminophenol; ICP 5 intra-cranial pressure; MELD 5 model for end-stage liver disease
score at time of initiation of ol-CVVHD-RCA; MV 5 mechanical ventilation; SOFA 5 sequential organ failure assessment. Initial score of
more than 11 is associated with a mortality rate >90%, while a score of 8-11 is associated with a mortality rate of 60%.

acetaminophen toxicity and much less with other etiologies.3,4 Cerebral edema (CE) is one of the most common
complications, and occurs in up to 80% of patients with
severe encephalopathy.1 Without liver transplantation, the
mortality rate is around 30% usually in the setting of
infection and CE.1,4–7 The etiology of CE is multifactorial
and not fully understood. It might result from increased
brain water content induced by the accumulation of
osmotically active glutamine derived from ammonia in the
astrocytes.8 Rapid dialytic removal of urea and other uremic solutes might also induce or exacerbate CE.9–11
Several strategies have been implemented to prevent and
treat CE, with induction of systemic plasma hypertonicity
using hypertonic saline or mannitol therapy being the
cornerstone of management. In patients suffering from
concomitant kidney injury, plasma hypertonicity can be
regulated by adjusting the prescription of continuous renal
replacement therapy (CRRT) to achieve and maintain a
specific higher systemic sodium level ([Na]Sys). Herein, we
describe our experience regulating plasma hypertonicity in
ALF using a high-sodium online-generated dialysate with
24-hour continuous veno-venous hemodialysis and
regional citrate anticoagulation (ol-CVVHD-RCA).

METHODS
Patient selection
Since the implementation of our near-automated olCVVHD-RCA program at Henry Ford Hospital12,13 starting
in 2009, we used it to regulate plasma hypertonicity in
Hemodialysis International 2018; 22:184–191

most patients with ALF, CE, and AKI requiring CRRT.
Table 1 summarizes the demographics and clinical settings
of 11 consecutive patients who presented between January
2011 and July 2013. Our patients were severely ill with an
elevated predicted mortality rate thus ol-CVVHD-RCA was
our CRRT modality of first choice. Following an institutional protocol, five patients had an intra-cranial pressure
(ICP) monitor inserted after receiving hypertonic saline at
the first clinical or radiological signs of CE.

CRRT therapy
As previously described,12,13 we used a Fresenius 2008K
or K2 (Fresenius Medical Care, North America, Waltham,
MA, USA) machine in pediatric intermittent hemodialysis
(IHD) mode to deliver a blood flow (QB) of 60 mL/min
and a dialysate flow (QD) of 400 mL/min. CRRT is
achieved by running 9-hour 59-minute IHD sessions separated by a 20-second machine reset procedure. Vascular
access was established through central venous hemodialysis catheters. We used the high-flux and high-efficiency
Rexeed 15S hemodialyzer (Asahi-Kasei Corp., Tokyo,
Japan) which delivers a substantial dose of internal
hemofiltration-backfiltration due to its very high ultrafiltration coefficient. The delivered net ultrafiltration rate
ranged from 0 to 200 mL/hour (possible 0–500 protocol
range), based on individual settings. Online prescription
(selection from the machine screen menu) was used to
generate a dialysis fluid with a fixed sodium level up to
155 mEq/L (range 130–155). The conductivity of the
fresh dialysate was monitored and is a surrogate for the
final dialysate sodium concentration. Our 24-hour ol185
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Figure 1 Top: sodium fluxes across the dialyzer. Due to complete equilibrium with the dialysate [Na]out 5 [Na]Din, any infusion
or fluid loss which is not isotonic to [Na]Din will contribute to the arbitrary kinetic construct “sodium generation” G (mEq/h) as
defined in the figure; net ultrafiltrate is isotonic and thus is ignored. If all gain and loss of fluid is isotonic to [Na]Din then G will
be zero. QBe effective blood flow for sodium (blood water flow), QD dialysate flow, QUF ultrafiltration flow. All flows are in L/h.
[Na]in,out sodium concentration (mEq/L) at the dialyzer blood inlet and outlet, respectively. [Na]Din,Dout sodium concentration
(mEq/L) at the dialyzer dialysate inlet and outlet, respectively. Nain,out amount of sodium (mEq/24 h) gained or lost, respectively.
Kin,out amount of potassium (mEq/24 h) gained or lost, respectively. Vin,out volume of water (L/24 h) gained through infusion or
lost through drainage or loss of body fluids, respectively. R: access recirculation. Bottom: sodium kinetic equations. Equation 1
derives the Keff (effective urea clearance in L/h) after correcting dialyzer urea clearance (K, in L/h) for access recirculation. In our
venous-venous access model there is no cardiopulmonary recirculation. Therefore, as Equation 2 shows Keff can be measured by
the Kecn: effective conductivity clearance (L/h) which in turn is near equal to D (effective sodium dialysance in L/h). Equation 3
calculates the TBW(t) (TBW in L at time t) which is equal to the initial TBW(0h) derived from the EEW (estimated euvolemic
weight in Kg) using the Watson’s formula in addition to any weight gain which is considered 100% water. The latter is the difference between the DW(t) (daily weight at time t in Kg) and EEW. Finally, we derive Equation 4 to predict the patient’s systemic
sodium concentration. [Na]Sys(t) the systemic sodium concentration at time t (mEq/L). [Na]Sys(0h) the systemic sodium concentration at initiation of dialysis, t: time on dialysis (h). To avoid a more complex kinetic equation we assume that TBW is fixed, still
achieving clinically acceptable accuracy. We also assume that the correction factor applied when reporting serum Na concentrations from the clinical laboratory and the Donnan-factor on the dialyzer cancel each other out and therefore can be omitted.

CVVHD-RCA therapy delivers about 3 L of urea clearance
and sodium dialysance per hour and therefore was not
expected to provide a rapid, immediate increase in
[Na]Sys. Since CE is a medical emergency that necessitates
immediate intervention, all patients initially received
either 23.4% saline as intravenous boluses (“saline
bullets”) or a continuous infusion of 3% saline through a
central venous catheter. This maneuver provided the
desired acute rise in [Na]Sys and plasma tonicity, with olCVVHD-RCA then used to maintain the [Na]Sys within
the target range. Weaning of plasma hypertonicity was
186

dictated by radiologic and clinical signs of resolution of
CE. Owing to the availability of highly reliable conductivity
sensor technology standard on all modern hemodialysis
machines, we measured the effective ionic dialysance
(Kecn)14 during CRRT every 100 minutes and used it to
quantify the volume of systemic blood equilibrating with
the fresh dialysate sodium level ([Na]Din) while accounting
for the variation in plasma protein level, red blood cell permeability, and Donnan factor expected to occur in a critically ill patient. Figure 1 details our sodium kinetic
modeling, where Equation 4 was used to predict the
Hemodialysis International 2018; 22:184–191
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[Na]Sys.15 Sodium and potassium total content and total
body water (TBW) volume changes derived from the gain
or loss of fluids non-isotonic to [Na]Din were included in
the calculations and represented by the artificial kinetic
term, sodium generation per hour, G averaged over a
24-hour period. This was done to account for the nonnegligible effect on [Na]Sys of continuous dilute IV fluids
(e.g., catecholamines or N-acetylcysteine in 5% dextrosewater) often needed in the care of ALF patients. Sodium
lost with gastric secretions and stool was practically difficult to account for and was ignored. Urine output was negligible. For mathematical simplicity, we used single-pool
fixed-volume sodium kinetic modeling16 thus we did not
account for the changes in TBW induced by fluid administration or body fluid losses naturally or through ultrafiltration. Finally, the pre-filter use of hypernatremic citrate
infusion did not affect the return blood sodium level or
the [Na]Sys as the protocol ensured that the circuit blood
sodium was fully equilibrated to the fresh dialysate fluid
sodium level. Systemic citrate accumulation was avoided
even in the assumed absence of liver metabolism of citrate
as all the infused citrate (>95%) was dialyzed out in a single pass and hence never entered the systemic circulation.
The time, t in hours required to achieve the desired
[Na]Sys target was estimated predominantly from an equation using the prescriber set difference between the systemic sodium level and the fresh dialysate sodium level at
start of the CRRT modeling period ([Na]Sys(0h) 2 [Na]Din),
multiplied by the exponential term 2Deff 3 t/V 5
2Kecn 3 t/TBW (Figure 1). As we did not expect multicompartment sodium kinetics during our low efficiency
continuous dialysis modality,16 the single-pool fixedvolume sodium kinetic modeling equation was used:

½NaSysð0hÞ 2 ½NaDin


 e2Kecn  t=TBW 1 G=Kecn  12 e2Kecn  t=TBW

½NaSysðtÞ 5 ½NaDin 1



where the effective sodium dialysance Deff (L/hour) is
replaced by the about equal effective ionic dialysance Kecn
(L/hour) which in turn is very accurately and automatically measured by the dialysis machine about every 2
hours during CRRT. The Kecn is about equal to Keff which
represents the effective urea clearance and allows us to
express the delivered CRRT dose in terms of estimated
standard urea Kt/V. A standard urea Kt/V of 1.2 is about
equivalent to 30 mL/kg/hour of post-dilution equivalent
continuous urea clearance. The t is the time needed to
achieve the desired [Na]sys in hours, V the apparent volume of distribution of sodium in L and can be replaced
Hemodialysis International 2018; 22:184–191

by an estimate of the TBW. The calculation of the artificial
kinetic term G in mEq/hour is only needed if the patient
is experiencing large fluid gains or losses non-isotonic to
the fresh dialysate and can be ignored otherwise. During
the ol-CVVHD-RCA with QB of 60 mL/min, we recorded
around one-thousand Kecn readings with a mean 6
standard error of 55.44 6 0.1 mL/mn. Assuming a patient
with TBW of 45 L and [Na]Sys(0h) of 140 mEq/L without
the use of HS, a desired goal serum sodium of 153 mEq/L
at 24-hour into ol-CVVHD-RCA ([Na]Sys(24h)) and fresh
[Na]Din of 155 mEq/L, the NaRR (or the reduction of the
sodium difference between systemic sodium at start of the
ol-CVVHD-RCA session and the fresh dialysate sodium)
will be equal to 0.86, derived from: ([Na]Sys(24h) 2
[Na]Sys(0h))/([Na]Sys(0h) 2 [Na]Din). When using the
equation above, t required to reach steady state with
[Na]Sys 5 [Na]Din will be about 27 hours. These kinetic
predictions explain our clinical practice of using hypertonic saline initially to acutely raise the [Na]Sys concentration followed by the ol-CVVHD-RCA mostly to maintain
the goal [Na]Sys. During modeling we ignored the effect of
net ultrafiltration (fixed volume kinetic model) as it was
expected to be isotonic to the [Na]Din and hence not
impact the [Na]Sys significantly. We also did not calculate
the difference between the laboratory reported serum
sodium level and the blood water sodium concentration
nor the impact of the Donnan factor on sodium fluxes on
the dialyzer (fortuitously the effects of these latter simplifications essentially cancel out each other). The resulting
fixed volume, single-pool sodium dialysance equation is
simple enough for routine clinical use and appears to be
clinically sufficiently accurate during the conditions of olCVVHD-RCA.

RESULTS
The duration of high sodium ol-CVVHD-RCA treatment
ranged from 4 to 13 days. Within 24 hours of start, all
patients had their sodium levels at or around the specified
target. Severe hypernatremia or unexpected changes in
[Na]Sys did not occur in any patient. Similarly, the [Na]Sys
was maintained throughout the duration of therapy, and
was not significantly lowered despite the large loads of
free water used to deliver antibiotics and/or continuous
infusions of pressors and antidotes such as N-acetylcysteine in hypotonic IV fluids. Figure 2 provides details
regarding the actual [Na]Sys, the [Na]Sys goal, and the
prescribed fresh dialysate sodium concentration [Na]Din.
Using the ol-CVVHD-RCA approach, we did not encounter any complication related to citrate accumulation or
toxicity such as ionized hypocalcemia or abnormally high
187
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Figure 2 Individual serum, dialysis fluid, and target sodium levels. X-axis indicates time in days and Y-axis denotes serum
sodium concentration (mEq/L). Filled diamonds (䉬) and broken (- - -) lines indicate achieved serum sodium levels and dialysate sodium concentrations, respectively. Solid arrows indicate administration of 20 mL of 23.4% saline bolus. Shaded areas
indicate desired serum sodium concentration range. Note that identical serum sodium values throughout a day are superimposed. The decrease in the dialysate sodium indicates the weaning from osmotherapy and the disappearance of the broken
line indicated the stopping of CVVHD-RCA. Patients (2) and (5) died. Patients (5) and (8) depicted in the right lower corner
underwent the shortest duration of therapy. * sodium level likely a laboratory error; rechecked immediately and was 150
mEq/L.

total-to-ionized calcium ratio. One hundred and sixty
serum ionized calcium levels out of 162 were within normal laboratory reference of 1 to 1.3 mmol/L. Two values
of 0.91 and 1.33 mmol/L were of no clinical significance.
For patients who had an ICP monitor, we did not observe
any increase in the ICP at the start or throughout the olCVVHD-RCA therapy, including patients who received
this treatment the longest (Table 2). The modality-related
downtime was 53.5 hours of 1902 prescribed hours,
accounting for 2.81%. The patient suffering from BuddChiari syndrome as well as one patient with acetaminophen toxicity died despite maintaining target [Na]Sys
levels. Among the 9 patients who survived, none required
liver transplantation. Seven patients had normalization of
their serum creatinine and liver function tests, while the
remaining 2 had partial improvement in both organ functions and were discharged without requiring outpatient
dialysis and were lost to follow-up.

DISCUSSION
The regeneration of hepatocytes in patients surviving ALF
starts after 3 days17 with restoration of liver function
occurring within 10 days.18 Optimal organ support is crucial within this 10-day window while awaiting liver recovery, especially managing any concomitant AKI and CE.
Frequently used agents such as mannitol and hypertonic
saline are associated with various adverse events, including volume expansion and rebound CE especially during

sudden withdrawal without prior weaning.19–25 In this
paper, we assume that osmotherapy delivered through
the modification of the replacement/dialysate fluid
sodium level offers numerous advantages over the conventional methods. The desired [Na]Sys can be smoothly
maintained with less risk of hypernatremia, and gradually
reversed at the end of therapy with less risk for rebound
CE. In addition, the volume overload and the metabolic
disturbances resulting from the renal failure itself or from
the induced hypernatremia, such as metabolic acidosis,
hypokalemia, or hyperkalemia, can be easily addressed
and managed. The use of a modified dialysate sodium
concentration has been previously reported for the management of dysnatremias.26–28 In a 5 L bag, the sodium
concentration can be raised from 140 to 154 mEq/L by
the addition of 17.5 mL of 23.4% hypertonic saline
(sodium concentration of 4 mEq/mL). This approach has
three major drawbacks: significant financial cost of CVVH
compared to the much less expensive ol-CVVHD-RCA, an
additional workload imposed on the pharmacy personnel
who perform the mixing, and the risk of contamination
and errors during the injection of HS into the fluid bags.
The last concern is highly significant as fatal errors during
the compounding of replacement fluid bags have been
reported.29 For these reasons, many hospital pharmacies
prohibit the modifications of CRRT fluid bags. Moreover,
the weaning phase of hypernatremia when the target
serum sodium [Na]Sys is gradually decreased might be difficult with the need for repetitive calculations. All of these

Table 2 Intra-cranial pressure values before and during ol-CVVHD-RCA
Case No
4
5
9
10
11

At insertion of
ICP monitor

At initiation of
ol-CVVHD-RCA

6h

1d

2d

3d

4d

5d

6d

18
19
17
22
17

18
5
5
10
19

15
13
9
19
19

10
5
8
12
5

6
95
2
18
8

8
111
3
14
2

7

9

7

4

4

9

7d

6

2

Intra-cranial pressure (ICP) values in mmHg of five patients who had an ICP monitor insertion. Data represents ICP at the time of insertion of the ICP monitor, at the initiation of ol-CVVHD-RCA, after 6 h, and up to 7 d. All patients received hypertonic saline before the
insertion of the ICP monitor due to radiographic signs of cerebral edema and at initiation of ol-CVVHD-RCA. Patient 5 did not survive.
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represent possibilities for additional error and wasting of
incompletely utilized fluid bags. This ol-CVVHD-RCA
protocol offers numerous advantages over conventional
continuous RRT (CRRT), including much less cost, simpler logistics of therapy delivery, and less risk of dosing
errors. This method warrants less frequent laboratory testing given the general stability of the [Na]Sys, and helps the
intensive care team focus on addressing some of the other
complex issues. The weaning phase of hypernatremia specifically proved smoother, with the target sodium and
bicarbonate in the fresh dialysate adjusted as needed
through simply pressing a few buttons on the machine
screen. It is important to emphasize that citrate should
not be used in patients with ALF unless the single pass
dialyzer removal of citrate exceeds at least 80% (95–98%
in the current protocol). In addition, the dialysis modality
used should have the least possible downtime to avoid
dangerous fluctuations in the serum sodium levels. A key
feature of our model is the ability to measure Kecn repeatedly and provide feedback about vascular access and dialyzer performances in delivering the prescribed sodium
dialysance. This is a crucial safety measure that eliminates
the risk of fluctuations in serum sodium level or lifethreatening citrate accumulation and toxicity in our
vulnerable patients with ALF. Additionally, the precise
delivery of hypernatremic therapy with this model
requires strict quality control of every step of dialysate
generation, which starts with the acid and bicarbonate
concentrate mixing process (performed by two trained
technicians working together) and ends with the final
proportioning on the dialysis machine. Dialysis technicians were available on-site 24/7 to answer any conductivity alarms.
CRRT in general might be the preferred method for
delivering both renal replacement therapy and high
plasma tonicity control in patients with ALF, owing to the
common occurrence of circulatory dysfunction resulting
in fragile hemodynamics. If IHD or higher intensity
hemofiltration (shift-therapy) are used for the management of the co-existing renal failure, they may worsen the
intra-cranial hypertension through the dialysis disequilibrium phenomenon, and through the induction of hypotension, which leads to a decrease in the cerebral
perfusion pressure and a reflex cerebral vasodilation,
thereby raising the ICP.30,31 These changes may occur
within the first hour of treatment, before any major
changes in plasma osmolality have occurred. Despite
CRRT being reported to avoid this problem,32,33 an
increase in ICP as early as 3 hours after initiation of
CVVH and SLED has been reported.34 The absence of
such findings in our patients might be owing to the
190

extremely low blood flow (60 mL/mn) and sodium dialysance or urea clearance of  55 mL/min.

CONCLUSION
The use of high sodium ol-CVVHD-RCA in general might
be superior to the conventional approach in the management of CE in the context of ALF and AKI. Our model in
particular is an effective, simple, and safe alternative for
maintaining and weaning a high target [Na]Sys. Although
it offers many advantages over conventional therapies, our
data cannot advocate the use of hypernatemia in patients
with CE but rather provides a reliable method of delivery
if this approach is to be pursued. This model is expected
to be further studied and small improvements to be made
with more experience. Finally, more data is needed to
clarify whether this proposed model will provide any
morbidity or mortality benefit beside optimizing and simplifying the treatment of CE in the described settings.
Manuscript received October 2016; revised March
2017.
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